Vivos Therapeutics Q4 2024: Contradictions in Marketing Strategy, Expansion Plans, and Cost Management
Tuesday, Apr 1, 2025 12:25 am ET
1min read These are the key contradictions discussed in Vivos Therapeutics' latest 2024Q4 earnings call, specifically including: Marketing Model and Revenue Impact, Sleep Centers and Expansion Strategy, Marketing and Sales Strategy, and Cost Management:
Revenue and Product Growth:
- Vivos Therapeutics reported total 2024 revenue of $15 million, a 9% increase from $13.8 million in 2023, driven by higher product revenue.
- The growth in product revenue was specifically from 16,182 oral appliance arches and guides sold, a 26% increase compared to the previous year.
Operating Loss Reduction:
- Vivos reduced its operating loss by 35% for the year, from $17.3 million in 2023 to $11.2 million in 2024.
- This reduction was attributed to higher revenue, gross profit, and lower SG&A expenses, primarily from cost-cutting efforts.
Marketing and Distribution Strategy:
- Vivos implemented a new marketing and distribution strategy, focusing on contractual profit-sharing alliances and acquisitions with sleep testing clinics and providers.
- This pivot was driven by the potential for Vivos to be at the table when critical treatment decisions are made, and it has led to an increase in the number of Vivos appliance placements.
International Expansion:
- Vivos expanded into the Middle East, gaining regulatory approvals and access to key markets like Dubai, Bahrain, Lebanon, and Qatar.
- This expansion was driven by the demand from the region, exceeding forecasts, and is expected to generate significant revenue growth.
Revenue and Product Growth:
- Vivos Therapeutics reported total 2024 revenue of $15 million, a 9% increase from $13.8 million in 2023, driven by higher product revenue.
- The growth in product revenue was specifically from 16,182 oral appliance arches and guides sold, a 26% increase compared to the previous year.
Operating Loss Reduction:
- Vivos reduced its operating loss by 35% for the year, from $17.3 million in 2023 to $11.2 million in 2024.
- This reduction was attributed to higher revenue, gross profit, and lower SG&A expenses, primarily from cost-cutting efforts.
Marketing and Distribution Strategy:
- Vivos implemented a new marketing and distribution strategy, focusing on contractual profit-sharing alliances and acquisitions with sleep testing clinics and providers.
- This pivot was driven by the potential for Vivos to be at the table when critical treatment decisions are made, and it has led to an increase in the number of Vivos appliance placements.
International Expansion:
- Vivos expanded into the Middle East, gaining regulatory approvals and access to key markets like Dubai, Bahrain, Lebanon, and Qatar.
- This expansion was driven by the demand from the region, exceeding forecasts, and is expected to generate significant revenue growth.
Ask Aime: What are the implications of Vivos Therapeutics' 2024Q4 earnings report on their market position and future growth strategy?
